This Week in Oncology — Jul 15, 2026

Editor's Pick: Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial (The Lancet. Oncology, 2026)
Welcome to This Week in Oncology. This week we are covering ten notable papers spanning targeted therapeutic strategies in solid tumors, proactive management of resistance in breast and gynecologic malignancies, new insights into hematologic treatment and screening, and advancements in supportive care. Let us dive in.
This week's papers:
• Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42441925)
• Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial. — The Lancet. Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42442380)
• Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial. — The Lancet. Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42442381)
• Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42447409)
• Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42441929)
• Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42447419)
• Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42441933)
• Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib. — Clinical Cancer Research 2026 (pubmed.ncbi.nlm.nih.gov/42446521)
• Virtual Sustained Tobacco Treatment for Patients With Cancer: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) Within the National Cancer Institute Community Oncology Research Program. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42441935)
• An anti-PMEL antibody-drug conjugate with a Ginhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial. — Nature Medicine 2026 (pubmed.ncbi.nlm.nih.gov/42443515)
Listen at AudioScholar (audioscholar.cc/episode/7ckam86ed7)